Aclaris Therapeutics Inc (FRA:8AT)
€ 1.0205 -0.004 (-0.39%) Market Cap: 74.98 Mil Enterprise Value: -35.52 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 48/100

Aclaris Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 10:15PM GMT
Release Date Price: €15.82 (+5.72%)
Unidentified Analyst

Good afternoon, everyone. Welcome. My name is [Lucy]. I'm an associate on the JPMorgan health care team. I have here with me Aclaris Therapeutics. I'm very honored to introduce to you the CEO, Doug; and we also have with us the CSO, Joe; and we also have with us on stage, the CMO, Gail; and we also have the CFO, Kevin, with us. All right. I'll leave things to you, Doug.

Douglas J. Manion
Aclaris Therapeutics, Inc. - CEO, President & Director

Great. So thank you, [Lucy], and thank you for -- to JPM for the kind invitation. I'm sure you all feel it's great to be seeing people in 3 dimensions again. So you all look great in 2 dimensions on Zoom, but it's a lot more from when you can interact with people directly. So I'm thrilled that that's the case. And I've been CEO only since last week, but I am honored to speak on behalf of the 100 employees of Aclaris Therapeutics and to share our story with you.

The slide deck that I'm presenting has been posted to our website. So you don't need to madly write down notes. You can just access it

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot